Paper No.6

Filed: November 21, 2023

UNITED STATES PATE	NT AND TRADEMARK OFFICE
BEFORE THE PATENT	TRIAL AND APPEAL BOARD
	UTICAL INDUSTRIES LTD. and TICAL INDUSTRIES, INC.,
P	etitioners,
	V.
	NORDISK A/S, tent Owner.
Issue D	o. 10,335,462 to Jensen ate: July 2, 2019 ag-Acting GLP-1 Peptides

PETITIONER'S UPDATED MANDATORY NOTICE UNDER 37 C.F.R. 42.8(a)(3)

Inter Partes Review No. IPR2024-00107



Pursuant to 37 C.F.R. § 42.8(a)(3), the undersigned on behalf of and acting in a representative capacity for Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries Inc. (collectively "Petitioner"), hereby submits the following mandatory change-of-information notices in connection with the petition for inter partes review of U.S. Patent No. 10,335,462, Case IPR2024-00107, to remove Mr. Christopher W. West as backup counsel for Petitioner.

#### A. Real Parties-In-Interest

In accordance with 37 C.F.R. § 42.8(b)(1), the real parties-in-interest for Petitioner are Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries Inc.

#### **B.** Related Matters

In accordance with 37 C.F.R. § 42.8(b)(2), Petitioner is not aware of any reexamination certificates or pending prosecution concerning the '462 patent. Petitioner is a defendant in the following consolidated litigation involving the '462 patent:

- Novo Nordisk Inc. and Novo Nordisk A/S v. Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries, Inc., No. 1:22-cv-00296 (D. Del.) (transferred to MDL on August 5, 2022);
- *In re Ozempic (Semaglutide) Patent Litigation*, No. 22-md-3038-CFC (D. Del.); and
- Novo Nordisk Inc. and Novo Nordisk A/S v. Rio Biopharmaceuticals, Inc. et al., No. 1:22-cv-00294 (D. Del.);

In addition, the following litigations also involve the '462 patent:



- Novo Nordisk Inc. v. Aurobindo Pharma USA, Inc., No. 1:22-cv-00295
   (D. Del.) (dismissed on March 28, 2022);
- Novo Nordisk Inc. v. Rio Biopharmaceuticals, Inc., No. 1:22-cv-00294 (D. Del.);
- Novo Nordisk A/S v. Sun Pharm. Indus. Ltd., No. 1:22-cv-00296 (D. Del.);
- Novo Nordisk Inc. v. Zydus Worldwide DMCC, No. 1:22-cv-00297 (D. Del.);
- Novo Nordisk Inc. v. Mylan Pharms. Inc., No. 22-cv-01040-CFC (D. Del.)
- Novo Nordisk Inc. v. Dr. Reddy's Laby's Ltd., No. 1:22-cv-00298 (D. Del.); and
- Novo Nordisk Inc. v. Alvogen, Inc., No. 1:22-cv-00299 (D. Del.).

Petitioner is not aware of any other pending litigation, or any pending proceedings in front of the Patent Trial and Appeal Board except for *Mylan Pharmaceuticals Inc. v. Novo Nordisk A/S*, Case No. IPR2023-00724 and *Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd. v. Novo Nordisk A/S*, Case No. IPR2024-00009.

# C. Identification of Counsel (37 C.F.R. § 42.8(b)(3))

Lead Counsel	Back-Up Counsel
Brian Sodikoff Reg No. 54,697 Katten Muchin Rosenman LLP 525 West Monroe Street Chicago, IL 60661 Phone: (312) 902-5200 Email: brian.sodikoff@katten.com	Christopher B. Ferenc Reg No. 59,365 Katten Muchin Rosenman LLP 1919 Pennsylvania Ave., N.W. Suite 800 Washington, DC 20006 Phone: (202) 625-3500 Email: christopher.ferenc@katten.com



# D. Service Information (37 C.F.R. § 42.8(b)(4))

Petitioner respectfully requests all correspondence be directed to lead counsel and back-up counsel at the contact information provided above.

Respectfully submitted,

Dated: November 21, 2023 By: <u>/Brian Sodikoff/</u>

Brian Sodikoff Reg No. 54,697

KATTEN MUCHIN ROSENMAN LLP

525 West Monroe Street

Chicago, IL 60661

Counsel for Petitioner

Sun Pharmaceutical Industries Ltd. and Sun Pharmaceuticals Industries, Inc.



### **CERTIFICATE OF SERVICE**

The undersigned certifies that the foregoing Petitioner's Updated Mandatory

Notice under 37 C.F.R. 42 were served on Patent Owner as follows:

J. Steven Baughman - steve.baughman@groombridgewu.com Megan Raymond - megan.raymond@groombridgewu.com Novo-Semaglutide-IPR@groombridgewu.com

Dated: November 21, 2023 By: /Brian Sodikoff/

Brian Sodikoff Reg No. 54,697

KATTEN MUCHIN ROSENMAN LLP

525 West Monroe Street

Chicago, IL 60661

Counsel for Petitioner Sun Pharmaceutical Industries Ltd. and Sun Pharmaceuticals Industries, Inc.

